Charles D Bengtson1, Robert N Montgomery1,2, Usman Nazir1, Lewis Satterwhite1, Michael D Kim1, Nathan C Bahr3, Mario Castro1, Nathalie Baumlin1, Matthias Salathe1. 1. Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, United States. 2. Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS, United States. 3. Department of Internal Medicine, Division of Infectious Diseases, University of Kansas Medical Center, Kansas City, KS, United States.
Abstract
Rationale: Coronavirus disease 2019 (COVID-19) can cause disruption of the renin-angiotensin system in the lungs, possibly contributing to pulmonary capillary leakage. Thus, angiotensin receptor blockers (ARBs) may improve respiratory failure. Objective: Assess safety of losartan for use in respiratory failure related to COVID-19 (NCT04335123). Methods: Single arm, open label trial of losartan in those hospitalized with respiratory failure related to COVID-19. Oral losartan (25 mg daily for 3 days, then 50 mg) was administered from enrollment until day 14 or hospital discharge. A post-hoc external control group with patients who met all inclusion criteria was matched 1:1 to the treatment group using propensity scores for comparison. Measures: Primary outcome was cumulative incidence of any adverse events. Secondary, explorative endpoints included measures of respiratory failure, length of stay and vital status. Results: Of the 34 participants enrolled in the trial, 30 completed the study with a mean age SD of 53.8 ± 17.7 years and 17 males (57%). On losartan, 24/30 (80%) experienced an adverse event as opposed to 29/30 (97%) of controls, with a lower average number of adverse events on losartan relative to control (2.2 vs. 3.3). Using Poisson regression and controlling for age, sex, race, date of enrollment, disease severity at enrollment, and history of high-risk comorbidities, the incidence rate ratio of adverse events on losartan relative to control was 0.69 (95% CI: 0.49-0.97) Conclusions: Losartan appeared safe for COVID-19-related acute respiratory compromise. To assess true efficacy, randomized trials are needed.
RCT Entities:
Rationale: Coronavirus disease 2019 (COVID-19) can cause disruption of the renin-angiotensin system in the lungs, possibly contributing to pulmonary capillary leakage. Thus, angiotensin receptor blockers (ARBs) may improve respiratory failure. Objective: Assess safety of losartan for use in respiratory failure related to COVID-19 (NCT04335123). Methods: Single arm, open label trial of losartan in those hospitalized with respiratory failure related to COVID-19. Oral losartan (25 mg daily for 3 days, then 50 mg) was administered from enrollment until day 14 or hospital discharge. A post-hoc external control group with patients who met all inclusion criteria was matched 1:1 to the treatment group using propensity scores for comparison. Measures: Primary outcome was cumulative incidence of any adverse events. Secondary, explorative endpoints included measures of respiratory failure, length of stay and vital status. Results: Of the 34 participants enrolled in the trial, 30 completed the study with a mean age SD of 53.8 ± 17.7 years and 17 males (57%). On losartan, 24/30 (80%) experienced an adverse event as opposed to 29/30 (97%) of controls, with a lower average number of adverse events on losartan relative to control (2.2 vs. 3.3). Using Poisson regression and controlling for age, sex, race, date of enrollment, disease severity at enrollment, and history of high-risk comorbidities, the incidence rate ratio of adverse events on losartan relative to control was 0.69 (95% CI: 0.49-0.97) Conclusions: Losartan appeared safe for COVID-19-related acute respiratory compromise. To assess true efficacy, randomized trials are needed.
Authors: Tomos E Walters; Jonathan M Kalman; Sheila K Patel; Megan Mearns; Elena Velkoska; Louise M Burrell Journal: Europace Date: 2017-08-01 Impact factor: 5.214
Authors: Renato D Lopes; Ariane Vieira Scarlatelli Macedo; Pedro Gabriel Melo de Barros E Silva; Renata Junqueira Moll-Bernardes; Andre Feldman; Guilherme D'Andréa Saba Arruda; Andrea Silvestre de Souza; Denilson Campos de Albuquerque; Lilian Mazza; Mayara Fraga Santos; Natalia Zerbinatti Salvador; C Michael Gibson; Christopher B Granger; John H Alexander; Olga Ferreira de Souza Journal: Am Heart J Date: 2020-05-13 Impact factor: 4.749
Authors: Genevieve L Y Rocheleau; Terry Lee; Yassene Mohammed; David Goodlett; Kevin Burns; Matthew P Cheng; Karen Tran; David Sweet; John Marshall; Arthur S Slutsky; Srinivas Murthy; Joel Singer; David M Patrick; Bin Du; Zhiyong Peng; Todd C Lee; John H Boyd; Keith R Walley; Francois Lamontagne; Robert Fowler; Brent W Winston; Greg Haljan; Donald C Vinh; Alison McGeer; David Maslove; Santiago Perez Patrigeon; Puneet Mann; Kathryn Donohoe; Geraldine Hernandez; James A Russell Journal: Crit Care Med Date: 2022-05-18 Impact factor: 9.296